Phosphorylation of ERalpha at serine 118 in primary breast cancer and in tamoxifen-resistant tumours is indicative of a complex role for ERalpha phosphorylation in breast cancer progression.

Sarwar, N; Kim, J-S; Jiang, J; Peston, D; Sinnett, H D; Madden, P; Gee, J M; Nicholson, R I; Lykkesfeldt, A E; Shousha, S; Coombes, R C; Ali, S

Sarwar, N; Kim, J-S; Jiang, J; Peston, D; Sinnett, H D; Madden, P; Gee, J M; Nicholson, R I; Lykkesfeldt, A E; Shousha, S; Coombes, R C; Ali, S.

Affiliation

Sarwar N; Department of Oncology, Imperial College London, Hammersmith Hospital Campus, UK.

Endocr Relat Cancer ; 13(3): 851-61, 2006 Sep.

Article in En | MEDLINE | ID: mdl-16954434

Subject(s)

Breast Neoplasms/metabolism; Estrogen Receptor alpha/metabolism; Phosphoserine/metabolism; Biomarkers, Tumor; Breast Neoplasms/drug therapy; Breast Neoplasms/pathology; Disease Progression; Drug Resistance, Neoplasm; Female; Humans; Immunohistochemistry; Phosphorylation; Prognosis; Tamoxifen/therapeutic use; Tumor Cells, Cultured

Search on Google

XML

PubMed Links

Collection: 01-internacional Database: MEDLINE Main subject: Phosphoserine / Breast Neoplasms / Estrogen Receptor alpha Type of study: Prognostic_studies Limits: Female / Humans Language: En Journal: Endocr Relat Cancer Journal subject: ENDOCRINOLOGIA / NEOPLASIAS Year: 2006 Type: Article Affiliation country: United kingdom

Search on Google

XML

PubMed Links